LD107 is a bill in the Maine Legislature (132nd Legislature): An Act to Require Health Insurance Coverage for Biomarker Testing.

What is the status of LD107?

Failed as of April 29, 2026. Latest action: Died in Possession of the Senate when the Legislature adjourned Sine Die and was PLACED IN THE LEGISLATIVE FILES. (DEAD) (April 29, 2026).

Samuel Zager (D, 116), with 7 co-sponsors.

Where is the official record for LD107?

On the Maine Legislature website: https://legislature.maine.gov/legis/bills/display_ps.asp?LD=107&snum=132

Maine legislation · 132nd Legislature

Maine LD107: An Act to Require Health Insurance Coverage for Biomarker Testing

Q: What does LD107 do?

In its own words: An Act to Require Health Insurance Coverage for Biomarker Testing" Amend the bill in section 1 in §3174-PPP in subsection 1 by striking out all of paragraph C (page 1, lines 16 to 22 in L.D.) and inserting the following: 'C. "Clinical utility" means, in the context of biomarker testing, that the use of biomarker testing is expected to provide meaningful information to guide decisions for the treatment of a disease or condition to improve net health outcomes, quality of life or survival of a patient, even if the results of biomarker testing are not immediately actionable in the course of a pati.

Status: Failed, April 29, 2026

What the bill says

An Act to Require Health Insurance Coverage for Biomarker Testing" Amend the bill in section 1 in §3174-PPP in subsection 1 by striking out all of paragraph C (page 1, lines 16 to 22 in L.D.) and inserting the following: 'C. "Clinical utility" means, in the context of biomarker testing, that the use of biomarker testing is expected to provide meaningful information to guide decisions for the treatment of a disease or condition to improve net health outcomes, quality of life or survival of a patient, even if the results of biomarker testing are not immediately actionable in the course of a pati.

From the introduced text:

An Act to Require Health Insurance Coverage for Biomarker Testing" Amend the bill in section 1 in §3174-PPP in subsection 1 by striking out all of paragraph C (page 1, lines 16 to 22 in L.D.) and inserting the following: 'C. "Clinical utility" means, in the context of biomarker testing, that the use of biomarker testing is expected to provide meaningful information to guide decisions for the treatment of a disease or condition to improve net health outcomes, quality of life or survival of a patient, even if the results of biomarker testing are not immediately actionable in the course of a patient's treatment.' Amend the bill in section 1 in §3174-PPP in subsection 2 in the 3rd line (page 1, line 33 in L.D.) by striking out the following: "is supported" and inserting the following: 'provides clinical utility as demonstrated' Amend the bill in section 1 in §3174-PPP in subsection 2 in paragraph D in the last lines (page 2, lines 2 and 3 in L.D.) by striking out the following: "Medicare administrative contractor local coverage determination" and inserting the following: 'a Medicare administrative contractor local coverage determination that is explicitly applicable in this State' Amend the bill in section 1 in §3174-PPP in subsection 2 in paragraph E in the first line (page 2, line 4 in L.D.) …

Read the full official text

Maine LD107: An Act to Require Health Insurance Coverage for Biomarker Testing

What the bill says

Sponsors

Latest actions

Common questions